We use cookies on our website to make it clear, useful and reliable.In order to achieve this and to provide certain personalised features we store a small amount of data about you. To learn more Click Here. By navigating from the front page to other sections of our website, you are consenting to information being stored.
Our latest news and events
Researchers and clinicians from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London and the South London and Maudsley NHS Foundation Trust will be part of a new trial involving four centres that will explore the potential therapeutic benefits of psilocybin on people living with anorexia nervosa.
By NIHR Maudsley BRC at 28 Jul 2022A new study from researchers supported by the NIHR Maudsley Biomedical Research Centre has found “substantial and concerning” gaps in the level of care being provided to people with depression. It also warns that those able to access care are “stagnating” in a system that results in their illness persisting for longer than it should.
By NIHR Maudsley BRC at 11 Jul 2022Parallel™ is the first prescription only digital therapeutic to provide cognitive behavioural therapy (CBT) to adults with irritable bowel syndrome (IBS) to receive the FDA Marketing Authorization in the US. ParallelTM has also obtained a CE mark and been recommended for Evaluation in Practice by the National Institute for Health and Care Excellence (NICE).
By NIHR Maudsley BRC at 1 Apr 2021
Naturally occurring lithium in public drinking water may have an anti-suicidal effect – according to a new study from Brighton and Sussex Medical School (BSMS) and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. Published in the British Journal of Psychiatry, the study collated research from around the world and found that geographical areas with relatively high levels or concentration of lithium in public drinking water had correspondingly lower suicide rates.
By NIHR Maudsley BRC at 27 Jul 2020Patients, carers and advocates say better evidence is needed on the safety of ketamine for depression after long-term use, and that those prescribed it must be closely monitored. These are the results of a study undertaken as part of a collaboration between the NIHR Maudsley Biomedical Research Centre (BRC) and NIHR Oxford Health Biomedical Research Centre (BRC).
By NIHR Maudsley BRC at 30 Jul 2019
The NIHR Maudsley Biomedical Research Centre (BRC) is part of the NIHR and hosted by South London and Maudsley NHS Foundation Trust in partnership with King's College London. We are part of King’s Health Partners Academic Health Sciences Centre.
